OpenAI has embarked on an ambitious initiative to create a fully automated AI researcher, positioning it as a central focus for the company over the next few years. This innovative project aims to develop an agent-based system capable of independently addressing complex research challenges. OpenAI plans to unveil an “autonomous AI research intern” by September 2024, which will initially handle a limited selection of research problems. This intern is envisioned as a stepping stone towards a comprehensive multi-agent research system expected to launch by 2028.
In a recent interview, OpenAI’s Chief Scientist Jakub Pachocki elaborated on these plans, emphasizing the potential for AI to revolutionize research methodologies. The goal is to enhance efficiency and effectiveness within the research community by leveraging AI’s capabilities to analyze vast datasets and generate insights autonomously.
Meanwhile, the exploration of psychedelic substances in clinical settings continues to reveal significant challenges. Recent studies highlight the complexities involved in researching compounds like psilocybin, which has garnered attention for its potential therapeutic applications in mental health treatment. Despite the growing enthusiasm surrounding psychedelics for conditions such as depression and PTSD, these investigations underscore the hurdles that need to be overcome. As the fascination with psychedelic drugs proliferates, these findings serve as a reminder of the rigorous scientific scrutiny required to validate their efficacy.
Source: The Download: OpenAI is building a fully automated researcher, and a psychedelic trial blind spot via MIT Technology Review